Edition:
United States

Profile: Rosetta Genomics Ltd (ROSG.O)

ROSG.O on Consolidated Issue listed on NASDAQ Capital Market

1.29USD
25 Sep 2017
Change (% chg)

$-0.07 (-5.15%)
Prev Close
$1.36
Open
$1.38
Day's High
$1.38
Day's Low
$1.26
Volume
226,987
Avg. Vol
104,423
52-wk High
$11.46
52-wk Low
$1.25

Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.

Company Address

Rosetta Genomics Ltd

10 Plaut Street, Science Park, P
REHOVOT     7670609
P: +9727.32220700
F: +9727.32220701

Company Web Links